This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Clover Biopharmaceuticals Future Growth

We currently don't have sufficient analyst coverage to forecast growth and revenue for Clover Biopharmaceuticals.

n/a

Earnings growth rate

190.4%

EPS growth rate

No updates

Earnings and Revenue Growth Forecasts

SHSC:2197 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	2,341	N/A	N/A	N/A	1
12/31/2024	3,071	N/A	N/A	N/A	2
12/31/2023	2,571	N/A	N/A	N/A	2
6/30/2023	0	-665	N/A	N/A	N/A
3/31/2023	0	-1,559	N/A	N/A	N/A
12/31/2022	N/A	-2,452	-1,796	-1,691	N/A
9/30/2022	N/A	-4,145	-1,461	-1,356	N/A
6/30/2022	N/A	-5,838	-1,125	-1,021	N/A
3/31/2022	N/A	-5,927	-1,062	-969	N/A
12/31/2021	N/A	-6,016	-998	-918	N/A
12/31/2020	N/A	-913	363	477	N/A

Earnings vs Savings Rate: Insufficient data to determine if 2197's forecast earnings growth is above the savings rate (1.9%).

Earnings vs Market: Insufficient data to determine if 2197's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 2197's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 2197's revenue (47.9% per year) is forecast to grow faster than the Hong Kong market (8.7% per year).

High Growth Revenue: 2197's revenue (47.9% per year) is forecast to grow faster than 20% per year.

Future ROE: Insufficient data to determine if 2197's Return on Equity is forecast to be high in 3 years time